How to Choose the Best Central American Country for Pharmaceutical Expansion
Not all Central American countries offer the same conditions for pharmaceutical expansion. While some stand out for their tax or logistical advantages, others offer opportunities based on market size or the role they can play in a regional strategy.
Comparing these differences helps companies understand what each market offers and how it can fit into an expansion plan.
Panama
Panama offers a combination of tax, logistical, and commercial advantages that make it an important location for regional operations. These include its dollarized economy, the Colón Free Zone and Panamá Pacífico free trade zones, which offer tax exemptions, and reduced rates on medical imports.
From a logistics perspective, the Panama Canal, Tocumen International Airport, and the Colón Free Zone facilitate product redistribution throughout Central America and the Caribbean. The document also highlights cold chain infrastructure for handling biologics and vaccines.
Additional competitive advantages include the use of the US dollar, the market’s purchasing power, confidence in European medicines within the private sector, and Panama’s role as a regional hub.
Costa Rica
Costa Rica has a Free Trade Zone Regime that offers tax and import exemptions, along with incentives for light manufacturing, packaging, and research and development.
The document also highlights the country’s biomedical cluster, connectivity through the ports of Limón and Caldera, and logistics infrastructure designed to support exports.
Its competitive advantages include the institutional reputation of its healthcare system, healthcare spending exceeding 6% of GDP, and its position as a market that can help European pharmaceutical companies establish credibility.
Guatemala
Guatemala offers free trade zones with customs exemptions and is the largest market in Central America, with approximately 17 million inhabitants.
The document highlights Puerto Quetzal and regional land connections as part of the country’s logistics infrastructure. It also points to a strong local generic pharmaceutical industry and an attractive population size.
El Salvador
El Salvador‘s tax advantages include the use of the US dollar, its maquila regime, free trade zones, and incentives for exporters.
From a logistics perspective, the document mentions the Port of Acajutla, a regional airport, and support from local operators. Its competitive advantages include a more direct public procurement model and a more stable market compared to Honduras and Nicaragua.
Honduras
Honduras offers free trade zones, incentives for maquila operations and exports, and Puerto Cortés as one of its main logistics assets.
The document identifies a mid-sized market with growth potential and less intense competition than in Guatemala and Panama as competitive advantages.
Nicaragua
Nicaragua offers free trade zones for maquila operations and exports, along with specific customs exemptions. Its logistics infrastructure also includes the ports of Corinto and El Rama.
The document describes Nicaragua as a small, politically influenced market and identifies entry through distributors as the most suitable alternative.
Belize
Belize offers tax benefits on imports and connections to the Caribbean through the Port of Belize City.
According to the document, it is a small market with simplified procedures due to its size and is typically served through distributors.
Each country offers a different combination of tax, logistical, and competitive advantages. The decision will depend on each pharmaceutical company’s expansion objectives.
Conclusion
The comparison highlights Panama and Costa Rica for their tax and logistical advantages; Guatemala for its market size; El Salvador and Honduras as mid-sized markets for regional expansion; and Nicaragua and Belize as markets that can be served through local distributors.